AR021757A1 - METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3 - Google Patents
METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3Info
- Publication number
- AR021757A1 AR021757A1 ARP990103961A ARP990103961A AR021757A1 AR 021757 A1 AR021757 A1 AR 021757A1 AR P990103961 A ARP990103961 A AR P990103961A AR P990103961 A ARP990103961 A AR P990103961A AR 021757 A1 AR021757 A1 AR 021757A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- type
- hydrogen
- androstan
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 4
- 238000006243 chemical reaction Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 title abstract 2
- 229960003473 androstanolone Drugs 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 229960003604 testosterone Drugs 0.000 title abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 101710172561 3alpha-hydroxysteroid dehydrogenase Proteins 0.000 abstract 3
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 150000002576 ketones Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 102000012394 17beta-dehydrogenases Human genes 0.000 abstract 1
- 108050002933 17beta-dehydrogenases Proteins 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 abstract 1
- 206010020112 Hirsutism Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229940124139 Hydroxysteroid dehydrogenase inhibitor Drugs 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039792 Seborrhoea Diseases 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000002996 androgenic alopecia Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 nitro, hydroxyl Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 201000007094 prostatitis Diseases 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Método para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona en un paciente quenecesita dicha inhibicion que comprende la administracion a dicho paciente de una cantidad terapéuticamente efectiva de un inhibidor de la 3 alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana. El inhibidor de la 3alfa-hidoxiesteroide deshidrogenasa de tipo 3 humana que posee la siguiente estructura: 1donde la línea de puntos es un enlace pi optativo; donde R3 es una porcion seleccionada del grupo formado por C1-20-alquiloxi, C1-10-aciloxi,C1-20-alcoxicarboniloxi, C1-20-alquiloxialquiloxi, hidroxilo, (N-alquil o -H)-carbamato y un grupo transformado in vivo en hidroxilo; donde R2 y R4 seseleccionan independientemente del grupo formado por hidrogeno, ciano, fluoro, cloro, bromo y nitro (donde R2 y R4 no son hidrogeno simultáneamente); dondeR17alfa se selecciona del grupo formado por hidogeno, una porcion carbonada de C2-14 sustituida porun radical seleccionado del grupo formado por hidrogeno,halogeno, carboxilo, amida, C1-3-alcoxi, C1-3-alquilo y fenilo sustituido con R100, donde R100 se selecciona del grupo formado por hidrogeno, carboxilo, amida,C1-5-alquilo, halo, nitro, hidroxilo y C1-3-alcoxi; o R17alfa y R18beta forman juntos un anillo C5-7-lactona o es un oxígeno cetonico; donde R17beta eshidroxilo, aciloxi, alcoxi, alqueniloxi, (N-alquil o H); o R17alfa y R17beta forman juntos un anillo C5-7-lactona o es un oxígeno cetonico; donde R16alfa yR16beta se seleccionan independientemente del grupo formado por hidrogeno, alquilo inferior y bencilo; o R16alfa y R16beta forman juntos a C5-6-cicloalqueno.Método de tratamiento y/o inhibicion del desarrollo del cáncer de prostata, hiperplasia prostática benigna, prostatitis,a cné, seborrea, hirsutismo o alopecíaandrogénica en los que se utilizan inhibidores de la 3-alfa hidroxiesteroide deshidrogenasa de tipo 3, solos o en combinacion con otros fármacos activos talescomo los inhibidores de la 17beta-deshidrogenasa de tipo 5. Un inhibidor de la 3alfa-hidroxiesteroide deshidrogenasa de tipo 5. Un inhibidor de la 3alfaMethod for inhibiting the conversion of 4-androstan-3,17-dione in testosterone or 3alpha-androstan-3,17-dione in dihydrotestosterone in a patient who needs said inhibition comprising the administration to said patient of a therapeutically effective amount of a human type 3 alpha-hydroxysteroid dehydrogenase inhibitor. The human type 3 3-alpha-hidoxysteroid dehydrogenase inhibitor that has the following structure: 1 where the dotted line is an optional pi bond; where R3 is a portion selected from the group consisting of C1-20-alkyloxy, C1-10-acyloxy, C1-20-alkoxycarbonyloxy, C1-20-alkyloxyalkyloxy, hydroxy, (N-alkyl or -H) -carbamate and a transformed group in vivo in hydroxyl; where R2 and R4 are independently selected from the group consisting of hydrogen, cyano, fluoro, chloro, bromo and nitro (where R2 and R4 are not hydrogen simultaneously); where R17alpha is selected from the group consisting of hydrogen, a carbonized portion of C2-14 substituted by a radical selected from the group consisting of hydrogen, halogen, carboxyl, amide, C1-3-alkoxy, C1-3-alkyl and phenyl substituted with R100, where R100 is selected from the group consisting of hydrogen, carboxyl, amide, C1-5-alkyl, halo, nitro, hydroxyl and C1-3-alkoxy; or R17alfa and R18beta together form a C5-7-lactone ring or is a ketone oxygen; where R17beta is hydroxy, acyloxy, alkoxy, alkenyloxy, (N-alkyl or H); or R17alfa and R17beta together form a C5-7-lactone ring or is a ketone oxygen; where R16alfa and R16beta are independently selected from the group consisting of hydrogen, lower alkyl and benzyl; or R16alfa and R16beta together form C5-6-cycloalkene. Method of treatment and / or inhibition of the development of prostate cancer, benign prostatic hyperplasia, prostatitis, cne, seborrhea, hirsutism or androgenic alopecia in which inhibitors of 3 -alpha hydroxysteroid dehydrogenase type 3, alone or in combination with other active drugs such as inhibitors of 17beta-dehydrogenase type 5. An inhibitor of 3alpha-hydroxysteroid dehydrogenase type 5. An inhibitor of 3alpha
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9562398P | 1998-08-07 | 1998-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021757A1 true AR021757A1 (en) | 2002-08-07 |
Family
ID=22252842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103961A AR021757A1 (en) | 1998-08-07 | 1999-08-06 | METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1102582A2 (en) |
| JP (1) | JP2002522380A (en) |
| CN (1) | CN1322130A (en) |
| AR (1) | AR021757A1 (en) |
| AU (1) | AU5144999A (en) |
| CA (1) | CA2339368A1 (en) |
| ID (1) | ID28791A (en) |
| NO (1) | NO20010651L (en) |
| WO (1) | WO2000007576A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
| EP1321146A3 (en) * | 1998-03-11 | 2004-06-02 | Endorecherche Inc. | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
| US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
| US6891953B1 (en) | 2000-06-27 | 2005-05-10 | Microsoft Corporation | Method and system for binding enhanced software features to a persona |
| US6995278B2 (en) | 2000-08-18 | 2006-02-07 | Entre Med, Inc. | Antiangiogenic agents |
| US7135581B2 (en) | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
| AU8838601A (en) * | 2000-11-27 | 2002-06-03 | Entremed Inc | Antiangiogenic agents |
| US6710037B2 (en) * | 2001-05-01 | 2004-03-23 | Schering Corporation | Method of treating androgen-dependent disorders |
| JP2003137814A (en) * | 2001-08-10 | 2003-05-14 | Takeda Chem Ind Ltd | COMBINED PHARMACEUTICAL OF GnRH AGONIST |
| DK1666033T3 (en) * | 2001-11-29 | 2009-04-06 | Gtx Inc | Prevention and treatment of osteoporosis caused by androgen deficiency |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| WO2005030120A2 (en) | 2003-05-28 | 2005-04-07 | Entremed, Inc. | Antiangiogenic agents |
| EP1756139A4 (en) | 2004-03-12 | 2009-07-29 | Entremed Inc | Antiangiogenic agents |
| US7419972B2 (en) | 2004-07-02 | 2008-09-02 | Schering Ag | 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 |
| DE102004032674A1 (en) * | 2004-07-02 | 2006-01-26 | Schering Ag | New 2-substituted Estra-1,3,5 (10) -triene-17-ones as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 |
| CA2646065C (en) | 2006-03-20 | 2014-01-14 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| US9284345B2 (en) * | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| DK2181990T3 (en) * | 2007-08-31 | 2012-09-10 | Astellas Pharma Inc | piperidine |
| CN101698834B (en) * | 2009-09-08 | 2012-05-23 | 北京利德曼生化股份有限公司 | 3 alpha-hydroxysteroid dehydrogenase and nucleotide sequence, recombinant vector, recombinant host cell and kit thereof |
| KR20150036319A (en) * | 2012-07-10 | 2015-04-07 | 바이엘 파마 악티엔게젤샤프트 | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
| HK1211592A1 (en) | 2013-02-21 | 2016-05-27 | 拜耳医药股份公司 | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3) |
| CN104873525A (en) * | 2014-02-27 | 2015-09-02 | 天津药物研究院 | 11 beta-hydroxysteroid dehydrogenase inhibitor and its pharmaceutical composition and use |
| CN104873520A (en) * | 2014-02-27 | 2015-09-02 | 天津药物研究院 | 11 beta-hydroxysteroid dehydrogenase inhibitor and its pharmaceutical composition and use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3562260A (en) * | 1965-08-23 | 1971-02-09 | Ormonoterapia Richter Spa | 2-carbonyl-estratrienes and method of their preparation |
| US4340602A (en) * | 1978-10-18 | 1982-07-20 | Wayne State University | Compositions inhibiting estrogen sulfotransferase activity |
| AU556749B2 (en) * | 1983-02-22 | 1986-11-20 | Liehr, J.G. | Pharmaceutical compositions of 2-fluoroestradiol |
| US4568673A (en) * | 1984-03-20 | 1986-02-04 | Wayne State University | Compositions inhibiting murine MXT ductal carcinoma |
| US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| TR200002784T2 (en) * | 1998-03-11 | 2000-12-21 | Endorecherche, Inc | Type 5 and type 3 17beta-Hydroxysteroid dehydrogenase inhibitors and methods for their use |
-
1999
- 1999-08-06 AU AU51449/99A patent/AU5144999A/en not_active Abandoned
- 1999-08-06 ID IDW20010531A patent/ID28791A/en unknown
- 1999-08-06 CA CA002339368A patent/CA2339368A1/en not_active Abandoned
- 1999-08-06 WO PCT/CA1999/000724 patent/WO2000007576A2/en not_active Ceased
- 1999-08-06 CN CN99811739A patent/CN1322130A/en active Pending
- 1999-08-06 AR ARP990103961A patent/AR021757A1/en unknown
- 1999-08-06 EP EP99936218A patent/EP1102582A2/en not_active Withdrawn
- 1999-08-06 JP JP2000563261A patent/JP2002522380A/en active Pending
-
2001
- 2001-02-07 NO NO20010651A patent/NO20010651L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2339368A1 (en) | 2000-02-17 |
| AU5144999A (en) | 2000-02-28 |
| CN1322130A (en) | 2001-11-14 |
| EP1102582A2 (en) | 2001-05-30 |
| JP2002522380A (en) | 2002-07-23 |
| WO2000007576A3 (en) | 2000-03-30 |
| NO20010651L (en) | 2001-04-05 |
| WO2000007576A2 (en) | 2000-02-17 |
| ID28791A (en) | 2001-07-05 |
| NO20010651D0 (en) | 2001-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021757A1 (en) | METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3 | |
| US5372996A (en) | Method of treatment of androgen-related diseases | |
| MY157898A (en) | Helix 12 directed steroidal pharmaceutical products | |
| RU94046057A (en) | INHIBITORS OF ACTIVITY OF TESTOSTERONE-5α-REDUCTASE, PHARMCOMPOSITION, METHOD OF INHIBITION OF TESTOSTERONE-5α-REDUCTASE ACTIVITY | |
| ES2125495T3 (en) | 4-AZA-ANDROSTANO 16 SUBSTITUTED INHIBITORS OF THE ISOENZYME 5-ALPHA-REDUCTASE 1. | |
| PE15095A1 (en) | DERIVATIVE OF ANDROSTENONE | |
| DK1480634T3 (en) | Selective androgen receptor modulators (SARM) for the treatment of benign prostatic hyperplasia | |
| TNSN07473A1 (en) | Helix 12 directed non-steroidal antiandrogens | |
| HUT60139A (en) | Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen | |
| BR9908592A (en) | Process for inhibiting the activity of 17ß-hydroxysteroid dehydrogenase type 5, pharmaceutical composition, 17ß-hydroxysteroid dehydrogenase type 5 inhibitor, process for inhibiting 17ß-hydroxysteroid dehydrogenase type 3, 17ß-hydroxysteroid dehydrogenase type 3, processes to treat, or reduce the risk of developing, prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism or androgenic alopecia, polycystic ovary syndrome, breast cancer, endometriosis or leiomyoma, to inhibit testicular hormone secretions, to treat early puberty, and, kit | |
| PT1019060E (en) | Androgen synthesis inhibitors | |
| ATE151635T1 (en) | COMPOSITION FOR THE TREATMENT OF HUMAN PROSTATE ADENOCARCINOMA | |
| MY131522A (en) | PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL | |
| PE20060379A1 (en) | DERIVATIVES OF 4-CYCLOALKOXYBENZONITRILES AS MODULATORS OF ANDROGEN | |
| EP1515754A4 (en) | BETA-2-GLYCOPROTEIN 1 IS AN INHIBITOR OF ANGIOGENESIS | |
| WO2001017479A3 (en) | Methods and compositions for preventing and treating prostate disorders | |
| WO2001022919A3 (en) | Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof | |
| Frye | Inhibitors of 50a-Reductase | |
| Kirby | Recent advances in the medical management of prostate cancer | |
| JPH07508290A (en) | 17α and 17β substituted acyl 4 azasteroids | |
| Sun et al. | A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia | |
| Mahler et al. | Clinical profile of a new non-steroidal antiandrogen | |
| MX2025009867A (en) | Methods for treating breast cancer | |
| NZ327041A (en) | 17-beta-cyclopropyl(amino/oxy) 4-aza steriods as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase | |
| Cabeza et al. | New progesterone esters as 5α-reductase inhibitors |